Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ilex MedicalXTAE:ILX 69 Receivables Turnover is 0.85 as of Mar. 2026. GuruFocus rates XTAE:ILX with a GF Score™ of 69/100 and a GF Value™ of ₪63.66 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Ilex Medical ranks worse than 78.55% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ilex Medical's Revenue for the
three
months ended in Mar. 2026 was ₪213.6 Mil. Ilex Medical's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₪250.7 Mil.
Hence, Ilex Medical's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.85.
Ilex Medical (XTAE:ILX) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Ilex Medical Receivables Turnover Related Terms
Ilex Medical Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Ilex Medical's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:ILX vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Ilex Medical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ilex Medical Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ilex Medical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Ilex Medical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ilex Medical (XTAE:ILX) has a Receivables Turnover of 0.85 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ilex Medical and its competitors. According to the industry distribution chart, Ilex Medical ranks #637 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 78.5%.
Is Ilex Medical's Receivables Turnover too high?
Ilex Medical's current Receivables Turnover is 0.85. The Medical Devices & Instruments industry median Receivables Turnover is 5.58. Ilex Medical's value of 0.85 is 84.8% below this industry median. Based on the distribution chart, Ilex Medical ranks #637 out of 811 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Ilex Medical has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ilex Medical's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ilex Medical ranks #637 out of 811 companies for Receivables Turnover. This places Ilex Medical in the lower half of its industry. The industry median Receivables Turnover is 5.58. Ilex Medical's value of 0.85 is 84.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.58, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ilex Medical's current Receivables Turnover of 0.85 is 84.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ilex Medical and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ilex Medical's current Receivables Turnover is 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ilex Medical stock overvalued right now?
Based on GuruFocus' analysis, Ilex Medical (XTAE:ILX) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪63.66, compared to a current price of ₪51.60 — trading 18.9% below its estimated fair value. The current Receivables Turnover is 0.85 and 84.8% below the Medical Devices & Instruments industry median of 5.58. Ilex Medical's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Ilex Medical (XTAE:ILX), the current Receivables Turnover is 0.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ilex Medical (XTAE:ILX) Overvalued in 2026?
Based on GuruFocus' analysis, Ilex Medical stock appears to be undervalued.
The current stock price of ₪51.60 is trading 18.9% below its estimated GF Value™ of ₪63.66.
GuruFocus considers Ilex Medical to be Modestly Undervalued.
Key valuation signals for XTAE:ILX:
Receivables Turnover: 0.85
GF Value™: ₪63.66 vs. price of ₪51.60 (18.9% below fair value)
Industry Position: 84.8% below the Medical Devices & Instruments median (#637 of 811)
No single metric tells the full story. See the XTAE:ILX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ilex Medical Ltd is an Israel based company engages in the marketing and distribution of diagnostic products and other medical laboratory information systems. It offers in-vitro diagnostic equipment, reagents, laboratory management software, blood bank diagnostic kits, and diagnostic support services to the healthcare sector in Israel.
69GF Score
Get the complete analysis for XTAE:ILX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:ILX has been successfully added to your 
